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Andromachi ScaradavouThe fetus inherits one HLA haplotype from the
father (ie, inherited paternal antigens [IPA]) and one
HLA haplotype from the mother (ie, inherited mater-
nal antigens [IMA]) (Figure 1). During pregnancy, bi-
directional transplacental trafficking of cells exposes
the fetus to maternal cells expressing both IMA and
noninherited maternal antigens (NIMA), resulting in
the development of NIMA-specific responses. Fur-
thermore, fetal cells enter the maternal circulation,
sensitizing the mother to the IPA of the fetus [1,2].FETALTOLERANCE TO NIMA
The ‘‘NIMA effect’’ has been studied extensively.
A possible mechanism for this effect, proposed by
Mold et al. [3], involves the development of CD41
CD251Fox1 regulatory T cells that suppress fetal
responses specifically to NIMA. The presence of reg-
ulatory T cells has been implicated in the role of
NIMA in related kidney [4] and related hematopoi-
etic stem cell transplantations [5]. Recent studies
also indicate that these regulatory T cells are respon-
sible for suppressing the expansion of donor alloreac-
tive cells that cause graft-versus-host disease
(GVHD). Importantly, however, they do not abro-
gate the cytotoxic effect of the graft-versus-tumor
function [6]. An alternative mechanism, proposed by
Mommaas et al. [7], is that cord blood (CB) carries
NIMA-specific cytotoxic CD8 T cells capable of lys-
ing targets in vitro. Additional evidence for the pres-
ence of cytotoxic and regulatory CD8 cells in CB
comes from the study of van Halteren et al. [8], whichidentified CD8 cells against maternal minor H anti-
gens in offspring.MATERNAL MICROCHIMERISM IN FETUS
AND CB
Small numbers of maternal cells can be detected in
fetal tissues [9], as well as in CB samples [10]. Some of
these maternal cells are memory lymphocytes, which
can persist for long times. These maternal T cells
have been exposed and sensitized to the IPA expressed
on the fetal calls that enter in the maternal circulation.
The presence of anti-IPA cells may be responsible for
the superior outcomes of haploidentical T cell–
depleted transplantations from maternal donors com-
pared with those from paternal donors [11].MATERNAL–FETAL INTERACTIONS AFFECT
UNRELATED CB TRANSPLANTATION
OUTCOMES
The first study to evaluate the impact of fetal expo-
sure to NIMA on the outcome of unrelated CB trans-
plantations was published in 2009 [12]. The hypothesis
that exposure to NIMA during fetal life would have an
effect on transplantation outcomes in cases with an
NIMA match between CB donor and recipient was
evaluated in 1,121 patients with hematologic malig-
nancies who received single-unit CB grafts from the
New York Blood Center. Patients were assigned in
3 groups: those with 0 mismatched (MM) grafts
(n 5 62; 6% of total), those with HLA-MM, NIMA-
matched (M) grafts (n 5 79; 7% of total), and those
with HLA-MM, no NIMA-M grafts (n 5 980). Of
note, NIMA matching was assigned retrospectively,
so matches occurred only by chance; the CB grafts
were not selected based on NIMA.
The analysis showed statistically significant im-
provements in transplantation-related mortality, over-
all mortality, and treatment failure for HLA-MM,
NIMA-M grafts, as well as improved engraftment,
particularly in recipients of lower cell doses. Overall,
outcomes of 1 HLA-MM, NIMA-M grafts were
Figure 1. IPA and NIMA effects during pregnancy.
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transplantation relapse tended to be lower in patients
with myeloid malignancies who received 1 HLA-
MM, NIMA-M CB units. Recipients of HLA-MM,
NIMA-M grafts had no increased incidence of
GVHD [12].
The study by Rocha at al. [13] published in this
issue of Biology of Blood and Marrow Transplantation
aimed to confirm the superior outcomes of HLA-
MM, NIMA-M CB grafts. Using a smaller patient
cohort and a different analytic approach, the authors
compared results in 48 recipients of HLA-MM,
NIMA-M CB grafts and 118 recipients of HLA-
MM, NIMA-MM CB grafts. This study also as-
signed NIMA matches retrospectively, using similar
assignments as in the New York Blood Center anal-
ysis (although not described in detail). Among the
508 eligible patients, the frequency of NIMA-M
CB grafts was 8.5%. Importantly, in this study,
transplantation-related mortality was lower in recip-
ients of NIMA-M grafts (RR, 0.48; P 5 .05). Con-
sequently, overall survival was higher after NIMA-M
CB transplantations; the 5-year probability of over-
all survival was 55% with NIMA-M grafts versus
38% with NIMA-MM grafts (P 5 .04). Outcomes
of 1 HLA-MM, NIMA-M transplantations are not
shown separately in this analysis, to allow direct
comparison with the previous study [12]. No effects
on engraftment, incidence of GVHD, or relapse
were detectable.WHATARE THE NEXT STEPS?
Transplantation with HLA-MM, NIMA-M CB
grafts was not associated with adverse effects in either
study. Furthermore, using different analytical ap-
proaches, both studies showed significantly improved
posttransplantation survival. Although the precise
mechanism remains unclear, the previous work on
the effects of NIMA on transplantation supportsfurther study. Moreover, the recent finding of a lower
relapse rate in patients with hematologic malignan-
cies who shared IPA targets with their CB donors
[14] further highlights the beneficial role of fetal–
maternal interactions and warrants additional studies
in this area.
To overcome the low frequency of NIMA-M
grafts occurring just by chance and involving the
more common HLA antigens [13], preferential selec-
tion of NIMA-M CB units will substantially increase
the number of patients that can be evaluated in a rela-
tively short time. This strategy will require HLA typ-
ing of the CB donor mothers, to allow assignment of
NIMAs before final CB unit selection. The approach
may be somewhat complex, but the first steps have
already been implemented by Bone Marrow Donors
Worldwide, with the inclusion of NIMA in CB search
algorithms [15]. Another important consideration is
evaluation of the NIMA effect in the outcomes of the
large proportion of patients receiving double-unit
CB grafts.WHATARE THE IMPLICATIONS?
Unrelated CB is an increasingly used alternative
stem cell source for patients requiring hematopoietic
reconstitution, particularly those of ethnic minorities.
Despite the expanding worldwide inventory (approxi-
mately 600,000 CB units according to theWorldMar-
row Donors Association), the majority of patients do
not receive HLA-A, -B, -DRB1 M HLA grafts [16].
Including NIMA in the search algorithm allows for
the selection of ‘‘permissible’’ mismatches that lead
to superior clinical outcomes. The numerical improve-
ment in the probability of finding donor grafts by in-
cluding NIMA in CB searches is currently under
evaluation (van der Zanden et al., manuscript in prep-
aration). The cost-effectiveness of such an approach
must be assessed, considering the costs of adding
a large number of new, HLA-diverse CB units to
the inventory (for the banks) or the costs related to
posttransplantation complications (for the transplan-
tation centers).CONCLUSION
Paraphrasing Rocha et al. the statistically signifi-
cant survival advantage associated with NIMA-
matched transplantations cannot be ignored. CB
banks need to implement maternal HLA typing on
CB units, and transplantation centers should use
NIMA in CB selection algorithms and select CB
units that lead to improved transplantation outcomes,
enhancing the overall efficacy of unrelated CB trans-
plantation.
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